KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Other Non-Current Liabilities (2018 - 2025)

Twist Bioscience (TWST) has disclosed Other Non-Current Liabilities for 8 consecutive years, with $741000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 82.06% to $741000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $741000.0 through Dec 2025, up 82.06% year-over-year, with the annual reading at $747000.0 for FY2025, 83.54% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $741000.0 at Twist Bioscience, down from $747000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $19.3 million in Q4 2021, with the low at $60000.0 in Q3 2022.
  • Average Other Non-Current Liabilities over 5 years is $2.3 million, with a median of $475000.0 recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities surged 9083.81% in 2021, then crashed 99.69% in 2022.
  • Over 5 years, Other Non-Current Liabilities stood at $19.3 million in 2021, then plummeted by 99.69% to $60000.0 in 2022, then soared by 691.67% to $475000.0 in 2023, then fell by 14.32% to $407000.0 in 2024, then skyrocketed by 82.06% to $741000.0 in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $741000.0, $747000.0, and $688000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.